CorporateInFocus

Syngene Reported 10% Growth in Revenue to Rs. 6414 Mn

Commenting on the results, Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Limited, said, “Syngene’s performance across all divisions has been positive through the year, and we expect a busy fourth quarter. As a result, we have raised our revenue growth guidance for the full year to high teens.

Sharing is caring!

Syngene International Limited announced its third quarter results. The Company reported revenue from operations growth of 10% year-on-year to Rs. 6,414 Mn, delivering 10% growth in profit before tax to Rs. 1,284 Mn. Profit after tax for the quarter was Rs.1,040 Mn, representing year-on-year growth of 2%. Growth in profit after tax was impacted by a lower effective tax rate in the third quarter last year due to a tax reversal and other factors.

For the nine months to December 31 2021, the Company delivered growth of 21% in revenue from operations to Rs.18,461 Mn and profit after tax, before exceptional items, was Rs 2,733 Mn, an increase of 12% compared the same period in the previous year. Based on the Company’s performance to date and the anticipated project deliveries in the fourth quarter, the Company updated the full year revenue growth guidance to high teens, from the mid-teen guidance shared at the beginning of the financial year.

Commenting on the results, Jonathan Hunt, Managing Director and Chief Executive Officer, Syngene International Limited, said, “Syngene’s performance across all divisions has been positive through the year, and we expect a busy fourth quarter. As a result, we have raised our revenue growth guidance for the full year to high teens.

A highlight for the quarter was the extension of our long-standing collaboration with Amgen Inc until 2026. Since 2012, Syngene has been partnering with Amgen on research and development to address some of the most serious diseases in the world. We are delighted with our joint commitment to not only extend the term of this partnership but also add a new state-of-the-art dedicated laboratory to accelerate the advancement of Amgen’s R&D projects.

The 5-year renewal of the long-standing contract with Amgen, coming on the heels of the 10-year contract extension signed with BMS last year, confirms the stability of both relationships and provides a clear perspective on the future of our Dedicated Centers.

I believe that Syngene is well-positioned to meet our clients’ evolving requirements and capture market opportunities as they arise.”

Quarterly Financial Highlights (All numbers are in Indian rupees in Million except margins)

 Q3 FY22Q3 FY21YoY Change (%)
Revenue from Operations6,4145,84510%
Total Revenue6,5436,0169%
EBITDA2,1631,93312%
EBITDA Margin (%)33%32% 
Profit Before Tax1,2841,16510%
Profit After Tax1,0401,022 (note [1])2%
Pat Margin16%17% 

 

 

 

9M FY22 Financial Highlights (All numbers are in Indian rupees in Million except margins)

 

 9M FY229M FY21YoY Change (%)
Revenue from Operations18,46115,25721% 
Total Revenue18,84215,71920% 
EBITDA5,8395,02616% 
EBITDA Margin (%)31%32%  
Profit Before Tax3,3602,77021% 
PAT before exceptional items2,7332,443 (note 1)12% 
PAT Margin (%)   15%  16%  
PAT After exceptional items   2,480 (note [2])2,4432%

SMEStreet Edit Desk

SMEStreet Edit Desk is a small group of excited and motivated journalists and editors who are committed to building MSME ecosystem through valuable information and knowledge spread.

Related Articles

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back to top button
%d bloggers like this: